Johnson & Johnson (JNJ)vsPrestige Brand Holdings Inc (PBH)
JNJ
Johnson & Johnson
$255.88
-3.66%
HEALTHCARE · Cap: $615.36B
PBH
Prestige Brand Holdings Inc
$49.95
-4.29%
HEALTHCARE · Cap: $2.39B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 8895% more annual revenue ($97.93B vs $1.09B). JNJ leads profitability with a 21.5% profit margin vs 17.5%. PBH appears more attractively valued with a PEG of 1.53. PBH earns a higher WallStSmart Score of 63/100 (C+).
JNJ
Buy57
out of 100
Grade: C
PBH
Buy63
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for JNJ.
Margin of Safety
-54.8%
Fair Value
$42.61
Current Price
$49.95
$7.34 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 25 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 28.6%
Generating 3.4B in free cash flow
Reasonable price relative to book value
Attractively priced relative to earnings
Strong operational efficiency at 26.8%
Areas to Watch
Moderate valuation
Expensive relative to growth rate
Earnings declined 1.0%
Expensive relative to growth rate
Weak financial health signals
Revenue declined 5.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.5% and operating margin at 28.6%.
Bull Case : PBH
The strongest argument for PBH centers on Price/Book, P/E Ratio, Operating Margin. Profitability is solid with margins at 17.5% and operating margin at 26.8%.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Bear Case : PBH
The primary concerns for PBH are PEG Ratio, Piotroski F-Score, Revenue Growth.
Key Dynamics to Monitor
JNJ profiles as a mature stock while PBH is a declining play — different risk/reward profiles.
PBH carries more volatility with a beta of 0.35 — expect wider price swings.
JNJ is growing revenue faster at 6.6% — sustainability is the question.
JNJ generates stronger free cash flow (3.4B), providing more financial flexibility.
Bottom Line
PBH scores higher overall (63/100 vs 57/100), backed by strong 17.5% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Prestige Brand Holdings Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Prestige Consumer Healthcare Inc., develops, manufactures, markets, distributes and sells over-the-counter (OTC) healthcare products in the United States and internationally. The company is headquartered in Tarrytown, New York.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?